This template was built with Webflow's free Prospero UI Kit. Learn more
If your child has just been diagnosed with an SCN2A-related disorder, you probably have more questions than answers right now. That is completely normal. This guide was written for you.
Take your time. Start with what feels most urgent, and come back to the rest when you are ready.
What to focus on in the first 30 days after an SCN2A diagnosis.
Learn your child's mutation type
Ask your geneticist whether the variant is gain-of-function, loss-of-function, or mixed. It influences which symptoms are likely and which treatments may fit.
Ask for specialist referrals
A pediatric neurologist experienced in genetic epilepsies or a neurogenetics specialist should join the care team. Wait times are long, so start early.
Join the SCN2A Global Contact Registry
Registering connects your family with the research community and keeps you notified about new studies and trials. Sign up here.
Organize medical records
Create a one-page summary with diagnosis, current medications, allergies, and emergency contacts. Bring it to every appointment.
SCN2A is the name of a specific gene. It provides the instructions for building a protein called Nav1.2, which is a sodium channel in the brain. Sodium channels are tiny gates on the surface of brain cells (neurons) that open and close to let sodium ions flow in and out. This flow of sodium is what allows neurons to send electrical signals to each other.
Nav1.2 is especially active during early brain development. It plays a critical role in how the brain forms connections, processes information, and controls movement. When the SCN2A gene works correctly, Nav1.2 channels open and close at the right times and in the right amounts. The brain develops and functions as expected.
Because Nav1.2 is so important to early brain development, changes in the SCN2A gene can have wide-ranging effects. These effects can include seizures, developmental delays, autism spectrum disorder, movement difficulties, and challenges with communication and learning. The specific combination of symptoms varies from person to person, even among people with the same mutation.
SCN2A belongs to a family of nine sodium channel genes (SCN1A through SCN11A). Each gene builds a slightly different sodium channel that operates in different parts of the body. SCN1A builds Nav1.1, which is associated with Dravet syndrome. SCN8A builds Nav1.6, another channel important in the brain. SCN2A builds Nav1.2, which has its own distinct role in brain development and function.
Most SCN2A mutations happen spontaneously. They are not inherited from either parent. These are called de novo mutations. During the complex process of DNA replication before a child is conceived or very early in embryonic development, a random error occurs in the SCN2A gene. Neither parent carries the mutation in their own DNA.
This is one of the first things many families need to hear: you did not cause this. Nothing you did or did not do during pregnancy led to your child's SCN2A mutation.
One concept that helps explain why SCN2A mutations cause different symptoms at different ages is the developmental transition between Nav1.2 and Nav1.6. During early brain development, Nav1.2 (built by SCN2A) is the dominant sodium channel at a critical part of the neuron called the axon initial segment. This is where the neuron decides whether to fire an electrical signal.
As the brain matures during the first year or two of life, Nav1.6 (built by SCN8A) gradually replaces Nav1.2 at the axon initial segment. This transition means that SCN2A mutations can have different effects depending on whether they disrupt brain function before, during, or after this switch.
The location and type of mutation within the SCN2A gene determine how the Nav1.2 protein is affected. Some mutations make the channel overactive. Others make it underactive. Some affect how the channel is built at all. This is why two children with SCN2A mutations can have very different symptoms and trajectories.
SCN2A mutations are broadly classified into categories based on how they change the Nav1.2 sodium channel's function. Understanding your child's mutation type is one of the most important pieces of information you can have, because it directly influences treatment decisions.
Gain-of-Function (GOF)
These mutations cause Nav1.2 channels to be overactive. The channels open too easily, stay open too long, or do not close properly. This leads to excessive electrical signaling in the brain. GOF mutations are most commonly associated with seizures that begin in the first few months of life, often within the first three months.
Loss-of-Function (LOF)
These mutations cause Nav1.2 channels to be underactive or nonfunctional. The channels may not open properly, may close too quickly, or may not be produced at all. LOF mutations are more commonly associated with autism spectrum disorder, intellectual disability, and seizures that begin later in childhood (typically after the first year of life).
Mixed Function
Some mutations have both gain-of-function and loss-of-function properties, or their functional effect is not yet fully characterized. Research is ongoing to better understand these variants.
Variants of Uncertain Significance (VUS)
Sometimes genetic testing identifies a change in the SCN2A gene, but researchers and clinicians do not yet have enough evidence to determine whether it causes disease. These are called variants of uncertain significance. A VUS classification may change over time as more research is completed.
SCN2A mutations can cause a range of conditions. The specific symptoms depend on the mutation type, its location within the gene, and individual factors that researchers are still working to understand.
Seizures are among the most common features of SCN2A-related disorders. In people with GOF mutations, seizures often begin within the first three months of life and can be severe. In people with LOF mutations, seizures may begin later and can present differently. Some people with SCN2A mutations develop epileptic encephalopathy, where frequent seizure activity itself contributes to developmental challenges.
SCN2A is one of the genes most strongly associated with autism. LOF mutations are more commonly linked to autism features, which may include challenges with social communication, repetitive behaviors, and sensory processing differences. Some children with SCN2A-related autism also have intellectual disability, while others do not.
Some people with SCN2A mutations experience movement difficulties including dystonia (involuntary muscle contractions), ataxia (coordination problems), and episodic ataxia (temporary episodes of uncoordinated movement). These movement issues can range from mild to significantly affecting daily life.
Many children with SCN2A mutations experience developmental delays in areas such as speech and language, motor skills, and cognitive development. The degree of delay varies widely. Some children are mildly affected, while others have more significant support needs.
The definitive way to diagnose an SCN2A-related disorder is through genetic testing. The most common approach is a gene panel test that sequences SCN2A along with other genes associated with epilepsy or neurodevelopmental disorders. Whole exome sequencing (WES) and whole genome sequencing (WGS) are broader tests that can also identify SCN2A mutations.
If your child has epilepsy that began early in life, autism with no identified cause, or unexplained developmental delays, ask your doctor about genetic testing. Early diagnosis can directly influence treatment decisions.
Genetic test results classify variants using a five-tier system: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. A genetic counselor can help you understand what your child's specific result means. If your child receives a VUS result, periodic follow-up is recommended because classifications can change as new research becomes available.
In addition to genetic testing, your child's medical team may use electroencephalography (EEG) to monitor brain electrical activity, magnetic resonance imaging (MRI) to examine brain structure, and developmental assessments to evaluate cognitive, motor, and communication skills. These tools help build a complete picture of how your child is affected and guide treatment planning.
Children with SCN2A-related disorders benefit from a multidisciplinary care team. Key specialists may include a pediatric neurologist (ideally one with experience in genetic epilepsies), a geneticist or genetic counselor, a developmental pediatrician, and therapists (physical, occupational, and speech). Your pediatrician serves as the coordinator connecting these specialists.
Medication management for SCN2A-related seizures depends heavily on mutation type. For GOF mutations, sodium channel blocking medications may be beneficial. For LOF mutations, sodium channel blockers should generally be avoided because they can worsen symptoms. This is why knowing your child's mutation type is so important. Always discuss medication changes with your child's neurologist.
If your child has seizures, work with your neurologist to create a seizure action plan. This document should outline what to do during a seizure, when to administer rescue medication, and when to call emergency services. Share copies with caregivers, teachers, and family members.
Keep a log of your child's seizures (if applicable), medications and dosages, developmental milestones, and any changes in behavior or function. This information is invaluable at medical appointments and helps your care team make informed decisions over time.
Many children with SCN2A-related disorders benefit from early intervention therapies. Speech and language therapy can address communication challenges, including augmentative and alternative communication (AAC) devices for children who are nonverbal or have limited speech. Occupational therapy helps with fine motor skills, sensory processing, and daily living skills. Physical therapy addresses gross motor development, strength, and coordination.
Children with SCN2A-related disorders may qualify for an Individualized Education Program (IEP) or a 504 plan. These legal frameworks ensure your child receives appropriate accommodations and services in school. Request an evaluation through your local school district. You have the right to be an active participant in developing your child's educational plan.
The ketogenic diet is a high-fat, low-carbohydrate diet that has been shown to reduce seizures in some people with epilepsy, including some individuals with SCN2A mutations. This is a medical diet that should only be started and monitored under the supervision of your child's neurologist and a specialized dietitian.
Caring for a child with a rare disease is demanding. Your own physical and emotional health matters. Connect with other SCN2A families who understand what you are going through. Build a support network. Accept help when it is offered. Caregiver burnout is real, and taking care of yourself is not selfish. It is necessary.
SCN2A research is advancing. Scientists are pursuing multiple therapeutic approaches including antisense oligonucleotides (ASOs), gene therapy, and drug repurposing. These approaches aim to either correct the underlying genetic problem or manage its downstream effects more precisely than current treatments can.
Clinical trials are the pathway from laboratory research to approved treatments. Some SCN2A-relevant trials are actively enrolling participants. Visit our Research page for the latest information on trials relevant to SCN2A families, or search ClinicalTrials.gov for current studies.
Families play a critical role in advancing SCN2A research. Joining the SCN2A Global Contact Registry helps researchers understand the full spectrum of SCN2A-related disorders. Participating in natural history studies, sharing de-identified data, and supporting the SCN2A Foundation all contribute to bringing treatments closer to reality.
One of the most isolating parts of a rare disease diagnosis is feeling like no one else understands. Connecting with other SCN2A families changes that. Families around the world are navigating the same questions, challenges, and hopes that you are.
The SCN2A Foundation is a family-founded nonprofit accelerating research and therapeutic development for SCN2A-related disorders. We connect families with scientists, clinicians, and each other. We fund targeted research. And we work every day to bring effective treatments closer for every child and adult living with SCN2A.
Join the SCN2A Global Contact Registry to connect with the research community. Follow the Foundation on social media for the latest updates. And reach out through our contact page with any questions. We are here for you.
Join the SCN2A Global Contact Registry to connect your family with the research community. Support the Foundation's work to accelerate treatments for every child living with SCN2A.
Join the RegistrySupport the FoundationMedical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your child's physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Accelerating research and treatment for SCN2A-related disorders.
Get the latest SCN2A research and community news.